Description
Background:
Risankizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19
subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Risankizumab was approved by
the U.S. FDA for treatment of moderate-to-severe plaque psoriasis in April 2019, and in vitro, has been more
potent in inhibiting IL-23 signalling than other drugs performing in the same IL-23 complex.
Intended Use:
For Estimation of Risankizumab (SKYRIZI) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!